HC Wainwright Issues Pessimistic Outlook for TNGX Earnings

Tango Therapeutics, Inc. (NASDAQ:TNGX) – Stock analysts at HC Wainwright lowered their Q3 2026 earnings per share estimates for shares of Tango Therapeutics in a research note issued to investors on Tuesday, August 18th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings per share of ($0.32) for the quarter, down from their prior forecast of ($0.26). HC Wainwright has a “Buy” rating and a $68.00 price objective on the stock. The consensus estimate for Tango Therapeutics’ current full-year earnings is ($1.36) per share. HC Wainwright also issued estimates for Tango Therapeutics’ Q4 2026 earnings at ($0.34) EPS, FY2026 earnings at ($1.34) EPS and Q1 2027 earnings at ($0.35) EPS.

Tango Therapeutics (NASDAQ:TNGX) last released its earnings results on Tuesday, August 11th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.05).

A number of other research analysts have also recently issued reports on TNGX. Stifel Nicolaus lifted their price objective on shares of Tango Therapeutics from $24.00 to $40.00 and gave the company a “buy” rating in a research note on Monday, April 27th. Weiss Ratings raised Tango Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Wedbush upped their price objective on Tango Therapeutics from $19.00 to $33.00 and gave the stock an “outperform” rating in a research report on Thursday, May 14th. Canaccord Genuity Group raised their price objective on Tango Therapeutics from $42.00 to $46.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Finally, Guggenheim lifted their target price on Tango Therapeutics from $32.00 to $35.00 and gave the company a “buy” rating in a research report on Wednesday, August 12th. Thirteen equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $43.46.

Tango Therapeutics Trading Down 0.9%

Shares of NASDAQ:TNGX opened at $25.20 on Thursday. The firm has a 50 day moving average of $28.62 and a 200-day moving average of $22.61. The stock has a market capitalization of $4.25 billion, a PE ratio of -29.65 and a beta of 1.16. Tango Therapeutics has a 12 month low of $6.25 and a 12 month high of $34.39.

Insiders Place Their Bets

In related news, insider Adam Crystal sold 27,000 shares of the firm’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $29.59, for a total transaction of $798,930.00. Following the completion of the transaction, the insider directly owned 115,743 shares of the company’s stock, valued at $3,424,835.37. This trade represents a 18.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 6.50% of the stock is owned by insiders.

Institutional Trading of Tango Therapeutics

Several institutional investors have recently added to or reduced their stakes in TNGX. BlackRock Inc. acquired a new stake in shares of Tango Therapeutics during the second quarter worth $388,826,000. Adage Capital Partners GP L.L.C. raised its position in shares of Tango Therapeutics by 322.5% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 10,607,924 shares of the company’s stock worth $93,986,000 after acquiring an additional 8,096,924 shares in the last quarter. TRV GP IV LLC acquired a new position in shares of Tango Therapeutics in the 2nd quarter valued at about $120,181,383,000. Jupiter Topco LLC acquired a new position in shares of Tango Therapeutics in the 2nd quarter valued at about $157,989,000. Finally, Caligan Partners LP bought a new stake in shares of Tango Therapeutics during the 4th quarter valued at about $33,047,000. 78.99% of the stock is currently owned by institutional investors.

Key Headlines Impacting Tango Therapeutics

Here are the key news stories impacting Tango Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its price target for TNGX to $68 from $66 and reiterated a Buy rating. The new target implies substantial upside from the referenced $25.20 share price, providing a positive valuation signal for investors. HC Wainwright Increases Tango Therapeutics Price Target to $68
• Positive Sentiment: The analyst’s long-term outlook remains constructive, with projected 2027 quarterly losses of $0.37 to $0.41 per share and a full-year loss estimate of $1.54 per share, while maintaining the Buy rating and $68 target.
• Neutral Sentiment: HC Wainwright expects Tango Therapeutics to remain unprofitable through 2026 and 2027, forecasting fiscal 2026 EPS of negative $1.34 and fiscal 2027 EPS of negative $1.54. These estimates reinforce the company’s development-stage profile and suggest that investor sentiment will remain tied to clinical and pipeline progress rather than current earnings.
• Negative Sentiment: HC Wainwright reduced its fiscal 2026 EPS forecast to negative $1.34 from negative $1.15. It also cut its third-quarter estimate to negative $0.32 from negative $0.26 and its fourth-quarter estimate to negative $0.34 from negative $0.27, indicating higher anticipated losses than previously expected.

Tango Therapeutics Company Profile

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.